Latest News for: Eisai

Edit

Insomnia Drugs Market Outlook 2026-2034: Trends, Shares, and Growth Analysis Featuring Merck & Co., Eisai ...

Business Wire 15 Dec 2025
DUBLIN--(BUSINESS WIRE)--The "Insomnia Drug Market Outlook 2026-2034 ... Key pharmacologic categories include non-benzodi .
Edit

Insomnia Drugs Market Outlook 2026-2034: Trends, Shares, and Growth Analysis Featuring Merck & Co., Eisai Co., Viatris, Perrigo Co., Neurim Pharmaceuticals and More - ResearchAndMarkets.com

Pharmiweb 15 Dec 2025
Leading companies include Merck & Co., Eisai Co., Ltd., Idorsia Ltd., and others, with strategic initiatives influencing market dynamics through collaborations and regional expansion ... Key Attributes Report Attribute Details. No ... Eisai Co. Ltd ... Dr ... .
Edit

Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security ...

JCN Newswire 11 Dec 2025
TOKYO, Dec 11, 2025 - (JCN Newswire) - Eisai Co., Ltd ... In the field of environmental conservation, Eisai has identified “Business activities with consideration for the global environment” as one of our material issues ... Eisai Co., Ltd.
Edit

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment ...

The Eagle-Tribune 04 Dec 2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started treatment at an early stage ... .
Edit

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment ...

JCN Newswire 04 Dec 2025
TOKYO and CAMBRIDGE, Mass., Dec 4, 2025 - (JCN Newswire) - Eisai Co., Ltd ... Haruo Naito, "Eisai") and Biogen Inc ... Eisai. Eisai Co., Ltd ... Eisai Europe, Ltd ... Emea-comms@eisai.net. Eisai Inc ... Libby_Holman@eisai.com ... Eisai Co., Ltd.
Edit

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025

JCN Newswire 03 Dec 2025
TOKYO, Dec 2, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters. Tokyo, CEO. Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code ... December 1, 4.35 PM PT) ... Eisai Co., Ltd ... Eisai Inc (U.S.) ... Libby_Holman@eisai.com.
Edit

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025

PR Newswire 03 Dec 2025
3, 2025 /PRNewswire/ -- Eisai Co., Ltd ... Eisai Co., Ltd ... For more information about Eisai, please visit www.eisai.com (for global headquarters ... For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.
Edit

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological ...

My Horry News 03 Dec 2025
2, 2025 /PRNewswire/ -- Eisai Co., Ltd ... Haruo Naito, "Eisai") ...
Edit

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early ...

Nasdaq Globe Newswire 28 Nov 2025
If approved, lecanemab would be the first and only anti-amyloid treatment ...
Edit

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early ...

JCN Newswire 28 Nov 2025
28, 2025 - (JCN Newswire) - Eisai Co., Ltd ... Haruo Naito, “Eisai”) and Biogen Inc ... Viehbacher, “Biogen”) announced today that Eisai has filed a new drug application for “LEQEMBI(R)” (brand name, generic name.
Edit

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan (Biogen Inc)

Public Technologies 28 Nov 2025
27, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd ... Eisai Co., Ltd ... Eisai Inc ... For more information about Eisai, please visit www.eisai.com (for global headquarters ... For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.
Edit

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application ...

JCN Newswire 26 Nov 2025
26, 2025 - (JCN Newswire) - Eisai Co., Ltd ... HaruoNaito, “Eisai”) and Biogen Inc ... Viehbacher, “Biogen”) announced today that Eisai has completed the rolling submission of the ...
Edit

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application ...

Nasdaq Globe Newswire 25 Nov 2025
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid ...
Edit

Notice on Discontinuation of Receiving Emails with Password-Protected Attachments (Eisai Co Ltd)

Public Technologies 25 Nov 2025
November 25, 2025 Eisai Co., Ltd ... Eisai previously adopted the PPAP* method, which separately sends password-protected files and corresponding passwords via email ... eisai-ppap-contact@hhc.eisai.co.jp ... Eisai Co.
Edit

Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose (BioArctic AB)

Public Technologies 25 Nov 2025
2025-11-25 13.37.00 CET BioArctic AB - Other information disclosed according to the rules of the Exchange Eisai completes U.S ... Lecanemab is the result of a strategic research alliance between BioArctic and Eisai.

Article Search

tools
×
×
×
×